How Many Patients Suffering Major Trauma Would be Eligible for a Pre-hospital Transfusion
Launched by HÔPITAL NOVO · Jul 9, 2024
Trial Information
Current as of June 26, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at how many patients who have suffered serious injuries, known as major trauma, could benefit from receiving blood transfusions before they reach the hospital. Researchers want to gather information that could help support the idea of giving blood products to patients right at the scene of the accident, rather than waiting until they arrive at the hospital.
To take part in this study, participants need to be adults over 18 years old who are receiving care from a specialized medical team for severe injuries. This includes patients who need to be transported to an emergency room or those who have sadly passed away while in care. The study is currently not recruiting participants, but it aims to collect data to improve trauma care in the future. It's important to know that some patients, like those with certain types of head injuries or those who didn't receive resuscitation, won't be eligible for this trial.
Gender
ALL
Eligibility criteria
- Inclusion Criteria :
- • Patients over 18
- • Taken care of by a MICU team from participating centres
- • Victims of major trauma requiring transport to an emergency/recovery unit or declared dead during care
- • Informed and did not object to the collection of his data for research purposes during his lifetime
- Exclusion Criteria :
- • Traumatological reason for departure not confirmed in the emergency medical services report
- • Patient care of by the MICU for secondary transport (transport from one hospital to another)
- • Patient died without resuscitation by a professional
- • Patient with manifest isolated closed head injury
- • Patient deprived of civil rights
About Hôpital Novo
Hôpital Novo is a leading clinical trial sponsor dedicated to advancing medical research and improving patient outcomes through innovative studies and rigorous scientific methodologies. With a strong emphasis on collaboration and ethical practices, Hôpital Novo partners with healthcare professionals and institutions to conduct high-quality clinical trials across various therapeutic areas. Their commitment to patient safety, data integrity, and regulatory compliance ensures that all research initiatives are conducted to the highest standards, ultimately contributing to the development of new treatments and therapies that enhance healthcare delivery.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Aulnay Sous Bois, , France
Beaumont Sur Oise, , France
Pontoise, , France
Saint Denis, , France
Patients applied
Trial Officials
Dr Dorian WOLFF
Principal Investigator
Hôpital NOVO
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported